Posting of annual report

RNS Number : 8671N
Ondine Biomedical Inc.
07 June 2022
 


 

Ondine Biomedical Inc.

("Ondine Biomedical", "Ondine" or the "Company")

 

Posting of Annual Report for the Year Ended 31 December 2021

 

Ondine Biomedical Inc. (AIM: OBI)  announces  that its Annual Report for the Year Ended 31 December 2021 was posted on 7th June 2022 and is available on the Ondine website at: https://ondinebio.com/investors/reports-documentation/

 

  **ENDS**


About Ondine Biomedical Inc.

Ondine Biomedical Inc. (AIM: OBI) is a Canadian headquartered, medical device company led by founder and CEO, Carolyn Cross. Ondine has developed a patented, painless, photodisinfection technology platform used in treatment and prevention therapies for a broad-spectrum of pathogens - including multidrug-resistant strains. Photodisinfection is a targeted antimicrobial which uses non-thermal light to activate a photosensitive agent. In a few minutes, this light-based therapy destroys the pathogens' cell membranes and surface proteins through an oxidative burst without impact on human tissue. 

Ondine has a pipeline of products, based on its patent protected photodisinfection platform, in various stages of development. Products include treatment of chronic rhinosinusitis, decolonisation of infections in burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and most recently, the development of topical antiviral therapy for the upper respiratory tract to reduce viral titres and transmission of respiratory viruses (e.g., SARS-CoV-2, influenza, RSV, etc.). Ondine's technology is approved in a number of jurisdictions and has been awarded the CE mark, as well as Qualified Infectious Disease Product and Fast Track status in the U.S. by the FDA.

 

For more information, please visit:  www.ondinebio.com or contact: 

 

Ondine Biomedical Inc.


Carolyn Cross, CEO

+001 (1) 604 669 0555



Strand Hanson Limited (Nominated and Financial Adviser)


James Harris, James Dance

+44 (0) 20 7409 3494



Arden Partners plc (Broker)


Ruari McGirr, Antonio Bossi

+44 (0) 20 7614 5900



Vane Percy & Roberts (Media Contact)


Simon Vane Percy, Amanda Bernard

+44 (0) 77 1000 5910

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSUNRORUSUNRAR
UK 100

Latest directors dealings